Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.

Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R.

Vasc Health Risk Manag. 2012;8:621-9. doi: 10.2147/VHRM.S37969. Epub 2012 Nov 12.

2.
3.

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.

Aroda VR, DeYoung MB.

Postgrad Med. 2011 Sep;123(5):228-38. doi: 10.3810/pgm.2011.09.2479. Review.

PMID:
21904106
4.

Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.

Brunton S, Davidson JA.

Clin Ther. 2016 Mar;38(3):582-94. doi: 10.1016/j.clinthera.2016.01.014. Epub 2016 Feb 28. Review.

PMID:
26926319
5.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

6.

Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

Minze MG, Klein MS, Jernigan MJ, Wise SL, Frugé K.

Pharmacotherapy. 2013 Jun;33(6):627-38. doi: 10.1002/phar.1240. Epub 2013 Apr 1. Review.

PMID:
23553357
7.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
8.

[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].

Lecube A, Bueno M, Suárez X.

Med Clin (Barc). 2014 Sep;143 Suppl 2:23-7. doi: 10.1016/S0025-7753(14)70105-8. Epub 2014 Oct 15. Review. Spanish.

PMID:
25437462
9.

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Gallwitz B.

Drug Saf. 2010 Feb 1;33(2):87-100. doi: 10.2165/11319130-000000000-00000. Review.

PMID:
20082536
10.

Once-weekly exenatide as a treatment for Type 2 diabetes.

Schauerhamer MB, Gurgle H, McAdam-Marx C.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):611-26. doi: 10.1586/14779072.2015.1038242. Review.

PMID:
26000560
11.

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

McCormack PL.

Drugs. 2014 Mar;74(3):325-51. doi: 10.1007/s40265-013-0172-6. Review.

PMID:
24435322
12.

Exenatide once weekly for the treatment of type 2 diabetes.

Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM.

Expert Opin Investig Drugs. 2009 Mar;18(3):359-67. doi: 10.1517/13543780902766802 . Review.

PMID:
19243286
13.

Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.

Mafong DD, Henry RR.

Curr Atheroscler Rep. 2008 Feb;10(1):55-60. Review.

PMID:
18366986
14.

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

Ryan GJ, Moniri NH, Smiley DD.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Review.

PMID:
23784159
15.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
16.

Once weekly exenatide: efficacy, tolerability and place in therapy.

Wysham C, Grimm M, Chen S.

Diabetes Obes Metab. 2013 Oct;15(10):871-81. doi: 10.1111/dom.12084. Epub 2013 Mar 24. Review.

PMID:
23425609
17.

Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.

Lindamood CA, Taylor JR.

Clin Ther. 2015 Mar 1;37(3):483-93. doi: 10.1016/j.clinthera.2015.01.003. Epub 2015 Feb 4. Review.

PMID:
25659912
18.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

19.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
20.

Exenatide once weekly: opportunities in the primary care setting.

Davidson JA, Nikkel C, Grimm M.

Postgrad Med. 2013 May;125(3):68-78. doi: 10.3810/pgm.2013.05.2662. Review.

PMID:
23748508

Supplemental Content

Support Center